Status:
UNKNOWN
Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children
Lead Sponsor:
Hôpital Necker-Enfants Malades
Conditions:
COVID-19
Eligibility:
All Genders
7-18 years
Brief Summary
The paediatric population present mild or asymptomatic form of SARS-CoV-2 infection. This study asses the frequency of patients with SARS-CoV2 Antibodies (Ab) (seroprevalence) and the neutralizing typ...
Detailed Description
Background of the study: The fraction of undiagnosed cases is a critical epidemiological characteristic that modulates the epidemic potential of SARS-CoV-2 emerging respiratory virus. These subjects ...
Eligibility Criteria
Inclusion
- any child over 7 days and under 18 years of age who has been hospitalized for no more than 4 days and who has a blood sample regardless of the symptoms;
Exclusion
- Any child under 7 days
Key Trial Info
Start Date :
April 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04490811
Start Date
April 9 2020
End Date
December 31 2021
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necker Hospital
Paris, France, 75014